Diabetic Macular Edema / Diabetic Retinopathy – Unmet Need – Detailed, expanded analysis: diabetic macular edema (US & EU)

Diabetic macular edema (DME) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors, such as Regeneron / Bayer’s Eylea, Roche / Novartis’s Lucentis, and Roche’s Avastin, are the most common pharmacotherapies for treating DME, owing to their proven efficacy and safety. AbbVie’s Ozurdex and Alimera Sciences’ Iluvien, two long-acting corticosteroid implants, are also used to treat DME. However, these drugs all have clinical shortcomings in terms of efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. Our content examines the key treatment drivers and analyzes the greatest areas of unmet need, thereby presenting the opportunities in this space.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for DME?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for DME?
  • What are the prevailing areas of unmet need and opportunity in DME?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new DME drug?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in March 2022

Key companies: Roche, Regeneron, Novartis, Bayer, AbbVie, Alimera Sciences

Key drugs: Eylea, Lucentis, Avastin, Ozurdex, Iluvien

Table of contents


launch Related Market Assessment Reports